KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.
David S HongMarwan G FakihJohn H StricklerJayesh DesaiGregory A DurmGeoffrey I ShapiroGerald S FalchookTimothy J PriceAdrian SacherCrystal S DenlingerYung-Jue BangGrace K DyJohn C KraussYasutoshi KubokiJames C KuoAndrew L CovelerKeunchil ParkTae Won KimFabrice BarlesiPamela N MunsterSuresh S RamalingamTimothy F BurnsFunda Meric-BernstamHaby HenaryJude NgangGataree NgarmchamnanrithJune KimBrett E HoukJude CanonJ Russell LipfordGregory FribergPiro LitoRamaswamy GovindanBob T LiPublished in: The New England journal of medicine (2020)
Sotorasib showed encouraging anticancer activity in patients with heavily pretreated advanced solid tumors harboring the KRAS p.G12C mutation. Grade 3 or 4 treatment-related toxic effects occurred in 11.6% of the patients. (Funded by Amgen and others; CodeBreaK100 ClinicalTrials.gov number, NCT03600883.).